Russell Investments Group
PTCT icon

Russell Investments Group’s PTC Therapeutics PTCT Stock Holding History

Russell Investments Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.1M Buy
418,025
+82,586
+25% +$5.96M 0.03% 529
2026
Q1 		$22.9M Buy
335,439
+64,691
+24% +$4.58M 0.02% 602
2025
Q4 		$20.6M Buy
270,748
+23,255
+9% +$1.69M 0.02% 620
2025
Q3 		$15.2M Buy
247,493
+115,744
+88% +$6.03M 0.02% 735
2025
Q2 		$6.43M Buy
131,749
+118,105
+866% +$5.61M 0.01% 1070
2025
Q1 		$695K Sell
13,644
-157,053
-92% -$7.84M ﹤0.01% 2181
2024
Q4 		$7.71M Sell
170,697
-61,542
-26% -$2.63M 0.01% 942
2024
Q3 		$8.62M Sell
232,239
-48,861
-17% -$1.64M 0.01% 897
2024
Q2 		$8.6M Sell
281,100
-20,690
-7% -$670K 0.01% 885
2024
Q1 		$8.78M Buy
301,790
+110,670
+58% +$3.1M 0.01% 884
2023
Q4 		$5.27M Sell
191,120
-29,319
-13% -$670K 0.01% 1109
2023
Q3 		$4.94M Buy
220,439
+30,803
+16% +$1.15M 0.01% 1086
2023
Q2 		$7.71M Sell
189,636
-50,280
-21% -$2.46M 0.01% 896
2023
Q1 		$11.6M Sell
239,916
-5,663
-2% -$259K 0.02% 704
2022
Q4 		$9.37M Buy
245,579
+9,497
+4% +$395K 0.02% 786
2022
Q3 		$11.8M Sell
236,082
-10,853
-4% -$532K 0.03% 685
2022
Q2 		$9.89M Buy
246,935
+27,944
+13% +$980K 0.02% 782
2022
Q1 		$8.17M Sell
218,991
-24,861
-10% -$958K 0.01% 916
2021
Q4 		$9.71M Buy
243,852
+22,462
+10% +$860K 0.02% 910
2021
Q3 		$8.24M Buy
221,390
+43,000
+24% +$1.77M 0.01% 978
2021
Q2 		$7.54M Buy
178,390
+93,674
+111% +$4.01M 0.01% 1089
2021
Q1 		$4.01M Buy
84,716
+19,152
+29% +$1.14M 0.01% 1471
2020
Q4 		$4M Sell
65,564
-15,278
-19% -$900K 0.01% 1362
2020
Q3 		$3.78M Sell
80,842
-14,535
-15% -$716K 0.01% 1303
2020
Q2 		$4.84M Buy
95,377
+19,960
+26% +$981K 0.01% 1112
2020
Q1 		$3.36M Buy
75,417
+928
+1% +$46.7K 0.01% 1176
2019
Q4 		$3.58M Buy
74,489
+16,088
+28% +$684K 0.01% 1409
2019
Q3 		$1.98M Buy
58,401
+48,879
+513% +$2.13M ﹤0.01% 1692
2019
Q2 		$428K Hold
9,522
– – ﹤0.01% 2310
2019
Q1 		$358K Hold
9,522
– – ﹤0.01% 2455
2018
Q4 		$327K Hold
9,522
– – ﹤0.01% 2458
2018
Q3 		$448K Hold
9,522
– – ﹤0.01% 2437
2018
Q2 		$321K Hold
9,522
– – ﹤0.01% 2533
2018
Q1 		$258K Hold
9,522
– – ﹤0.01% 2621
2017
Q4 		$159K Hold
9,522
– – ﹤0.01% 2707
2017
Q3 		$191K Hold
9,522
– – ﹤0.01% 2675
2017
Q2 		$175K Sell
9,522
-13,500
-59% -$182K ﹤0.01% 2716
2017
Q1 		$227K Sell
23,022
-13,056
-36% -$158K ﹤0.01% 2670
2016
Q4 		$403K Buy
+36,078
New +$379K ﹤0.01% 2538

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Russell Investments Group's PTCT Position: Q2 2026 in Review

Russell Investments Group increased its PTC Therapeutics (PTCT) stake by 25% in Q2 2026, buying an estimated $5.96M and bringing the position to 418,025 shares worth $34.1M. The position accounts for 0.03% of the portfolio, ranked #529.

Russell Investments Group first reported a position in PTCT in Q4 2016 and has held it in 39 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Russell Investments Group held 418,025 shares of PTC Therapeutics worth $34.1M as of Q2 2026.
  • Russell Investments Group bought 82,586 PTC Therapeutics shares in Q2 2026, an estimated $5.96M.
  • PTC Therapeutics made up 0.03% of Russell Investments Group's portfolio in Q2 2026, its #529 holding.
  • Russell Investments Group first reported a position in PTC Therapeutics in Q4 2016 and has held it in 39 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.